Jakafi

Incyte Down as FDA Extends Review Period of Jakafi for GVHD
Incyte Down as FDA Extends Review Period of Jakafi for GVHD
Yahoo/Zacks.com
Incyte
FDA
Jakafi
graft vs host disease
Flag link:
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
CP Wire
FDA
Incyte
Novartis
Jakavi
Jakafi
graft vs host disease
Flag link:
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
Incyte
graft vs host disease
Novartis
Jakafi
Flag link:
Incyte preps Jakafi expansion into graft-versus-host disease
Incyte preps Jakafi expansion into graft-versus-host disease
Biopharma Dive
Incyte
Jakafi
graft vs host disease
Flag link:
Biotech Firm Incyte Finds The Right Chemistry For Success
Biotech Firm Incyte Finds The Right Chemistry For Success
Forbes
Incyte
biotech
Jakafi
Flag link:
Does Incyte Have The Best Cancer Portfolio Among Mid-Cap Biotechs?
Does Incyte Have The Best Cancer Portfolio Among Mid-Cap Biotechs?
Barron's
Incyte
epacadostat
olumiant
Jakafi
immuno-oncology
Flag link:
What Were Incyte’s Revenue Streams in 3Q16?
What Were Incyte’s Revenue Streams in 3Q16?
Market Realist
Incyte
Jakafi
Iclusig
Flag link:
Gilead Fails to Beat Incyte’s Jakafi Drug
Gilead Fails to Beat Incyte’s Jakafi Drug
Investopedia
Gilead Sciences
Jakafi
Incyte
momelotinib
myelofibrosis
Flag link:
FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease (GVHD)
FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease (GVHD)
Yahoo
FDA
Incyte
Jakafi
breakthrough therapies
graft vs host disease
Flag link:
How Has Incyte’s Jakafi Performed in the US?
How Has Incyte’s Jakafi Performed in the US?
Yahoo/Market Realist
Incyte
Jakafi
Novartis
Flag link:
JAK inhibition for solid tumors flops, forcing Incyte to pull the plug on a slate of trials
JAK inhibition for solid tumors flops, forcing Incyte to pull the plug on a slate of trials
Fierce Biotech
Incyte
Jakafi
solid tumors
JAK inhibitors
Flag link:
ASCO '15: CTI Biopharma Takes on Myelofibrosis Drug Rival
ASCO '15: CTI Biopharma Takes on Myelofibrosis Drug Rival
TheStreet.com
ASCO
CTI BioPharma
myelofibrosis
pacritinib
Jakafi
Incyte
Flag link:
Incyte's Jakafi Gets FDA Approval for Polycythemia Vera
Incyte's Jakafi Gets FDA Approval for Polycythemia Vera
Yahoo/Zacks.com
Incyte
Jakafi
FDA
polycythemia vera
Flag link:
Incyte Building Blockbuster Drug One Disease At A Time
Incyte Building Blockbuster Drug One Disease At A Time
Investors.com
Incyte
Jakafi
myelofibrosis
Flag link:
Geron sells last drug in pipeline to J&J unit
Geron sells last drug in pipeline to J&J unit
Yahoo/Reuters
Geron
JNJ
imetelstat
Jakafi
myelofibrosis
Flag link:
Incyte's Jakafi Unlikely to Benefit Pancreatic Cancer Patients
Incyte's Jakafi Unlikely to Benefit Pancreatic Cancer Patients
TheStreet.com
Incyte
Jakafi
pancreatic cancer
Flag link:
Incyte Gains on Positive Jakafi Data
Incyte Gains on Positive Jakafi Data
Yahoo/Zacks.com
Incyte
Jakafi
polycythemia vera
ASCO
Flag link:
Show me the money: Which drugs made the top 10 list on upfront deals?
Show me the money: Which drugs made the top 10 list on upfront deals?
Fierce Biotech
biotech
GED-0301
Celgene
Nogra Pharma
AbbVie
Reata
Bardoxolone
Abbott Labs
Tradjenta
Eli Lilly
Boehringer Ingelheim
FG-4592
AstraZeneca
FibroGen
Pfizer
Bristol-Myers Squibb
Eliquis
Moderna
Forma Therapeutics
dimebon
Medivation
Jakafi
Novartis
Incyte
Flag link:
Incyte Shows Its Path Towards Growth
Incyte Shows Its Path Towards Growth
Seeking Alpha
Incyte
Jakafi
Flag link:
Incyte Has First-Mover Advantage
Incyte Has First-Mover Advantage
Motley Fool
Incyte
myelofibrosis
Jakafi
Novartis
Flag link:

Pages